Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAAV | ISIN: US68752L1008 | Ticker-Symbol: 2X7
Frankfurt
05.09.25 | 08:05
17,600 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ORTHOPEDIATRICS CORP Chart 1 Jahr
5-Tage-Chart
ORTHOPEDIATRICS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
17,50017,60017:03
GlobeNewswire (Europe)
59 Leser
Artikel bewerten:
(0)

OrthoPediatrics Corp. Announces Distribution Agreement with MY01 Inc.

WARSAW, Ind., Sept. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics announced today a new distribution partnership with MY01, an innovative medical technology company focused on transforming the diagnosis of limb perfusion injuries. This collaboration will expand access to MY01's Continuous Perfusion Sensing Technology (CPST) Platform for children and adolescents, a population at great risk for acute compartment syndrome.

Acute compartment syndrome is a time-sensitive emergency that disproportionately affects children with a floating elbow1, tibial2 and forearm3 fractures, and other orthopedic traumatic injuries4. Diagnosing acute compartment syndrome in pediatric patients can be challenging: children may struggle to verbalize pain, and early warning signs are often subtle.

"This partnership isn't just about scale, it's about impact," commented Andrew Morris, Chief Commercial Officer at MY01. "Children represent the group most at-risk for compartment syndrome, and with OrthoPediatrics we can ensure clinicians have access to the right tools, at the right time, to avoid unnecessary surgeries and life-altering complications such as limb loss for these patients."

"At OrthoPediatrics, we've always been driven by one goal: to help children whose lives have been impacted by orthopedic conditions," said Fady Rayes, Vice-President of Product Development. "Partnering with MY01 extends that mission into trauma monitoring, pairing innovative technology with our focus on education and surgeon support."

By combining MY01's CPST Platform with OrthoPediatrics' dedicated pediatric sales force and commitment to medical education, clinicians will gain the tools and training needed to reduce variability in care, ensuring optimized outcomes for all pediatric patients.

About MY01
Founded in 2019 and based in Montreal, MY01 envisions a world where every disease is quantifiable, allowing for precise, personalized care for all patients. Our Continuous Perfusion Sensing Technology (CPST) Platform has the potential to transform trauma programs by translating complex biological signs into dynamic, actionable, real-time data that supports better decision-making. This reduces variations in care and delivers improved outcomes, enabling hospitals to allocate resources as efficiently as possible. MY01 is currently operational in the USA, Europe, and Canada, setting new standards in healthcare.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics' global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

1 Blakemore, L. C., Cooperman, D. R., Thompson, G. H., Wathey, C., & Ballock, R. T. (2000). Compartment syndrome in ipsilateral humerus and forearm fractures in children. Clin Orthop Relat Res(376), 32-38. https://doi.org/10.1097/00003086-200007000-00006
2 Obey, M. R., Shlykov, M. A., Nickel, K. B., Keller, M., & Hosseinzadeh, P. (2023). Incidence and risk factors for acute compartment syndrome in pediatric tibia fractures. J Pediatr Orthop B, 32(4), 401-404. https://doi.org/10.1097/bpb.0000000000000985
3 Grottkau, B. E., Epps, H. R., & Di Scala, C. (2005). Compartment syndrome in children and adolescents. J Pediatr Surg, 40(4), 678-682. https://doi.org/10.1016/j.jpedsurg.2004.12.007
4 Bae, D. S., Kadiyala, R. K., & Waters, P. M. (2001). Acute Compartment Syndrome in Children: Contemporary Diagnosis, Treatment, and Outcome. Journal of Pediatric Orthopaedics, 21(5), 680-688.

Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406


© 2025 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.